Recent Updates
Recently added Catalysts
RADX Neutral Sentiment Score: 50/100

Ceasing to be a substantial holder

Tuesday, August 27, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has made several announcements regarding its clinical studies and updates. Notably, the company has dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01) and received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. The company continues to provide updates across its programs.

Market Sentiment Analysis

Full Press Release Details

• Announcements
• August 27, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• March 4, 2024
• Announcements
• December 9, 2021
• Announcements
• November 30, 2021
• Announcements
• December 9, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the latest update from Radiopharm Theranostics?

Radiopharm Theranostics has dosed its first patient in a Phase 1/2a clinical study of BetaBart.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate being studied by Radiopharm Theranostics.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA approval clinical study
Last updated: Aug 27, 2024